Syndax Pharmaceuticals (SNDX) Current Assets (2015 - 2026)

Syndax Pharmaceuticals' Current Assets history runs 12 years deep, the most recent figure standing at $471.2 million for Q1 2026.

• In Q1 2026, Current Assets fell 14.14% year-over-year to $471.2 million; the TTM figure through Mar 2026 stood at $471.2 million (down 14.14% YoY), while the FY2025 annual figure was $528.1 million, down 12.43% from the prior year.
• Current Assets for Q1 2026 stood at $471.2 million, down from $528.1 million in the prior quarter.
• The five-year high for Current Assets was $603.1 million in Q4 2024, with the low at $357.6 million in Q3 2022.
• The 5-year median for Current Assets is $453.9 million (2024), against an average of $470.6 million.
• The sharpest annual moves came in 2022 and 2026: Current Assets soared 50.59% in 2022, then slipped 14.14% in 2026.
• Syndax Pharmaceuticals' Current Assets stood at $489.8 million in 2022, then advanced by 18.6% to $580.9 million in 2023, then gained by 3.82% to $603.1 million in 2024, then fell by 12.43% to $528.1 million in 2025, then fell by 10.78% to $471.2 million in 2026.
• Business Quant data shows SNDX's Current Assets at $471.2 million in Q1 2026, $528.1 million in Q4 2025, and $529.8 million in Q3 2025.